The Use of Routine Laboratory 17‐Hydroxyprogesterone for Identification of Cases of 21‐Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Joseph McElvaney und 7 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, 17-alpha-Hydroxyprogesterone. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical outcome studies of 21‐hydroxylase deficiency congenital adrenal hyperplasia (21OHD CAH) may be subject to selection bias due to incomplete case ascertainment. This study aimed to develop a methodology for identifying existing CAH cases and explore its utility to study clinical outcomes.
Methods
17‐hydroxyprogesterone assays (17OHP) processed in NHS Greater Glasgow and Clyde between 2014 and 2022 were analysed based on 17OHP result (≥ 6 or < 6nmol/L), location, test frequency and clinical details. Identified cases were cross‐referenced against local clinical data logs. For confirmed cases, current age, sex, age at diagnosis, mortality status, most recent blood pressure (BP) and anthropometry were collected.
Results
Assay results from 57,011 cases were extracted and, of these, 116 (F:M, 81:35) had confirmed CAH but 66 (57%) were not reported by any local clinical data logs. The median age at the time of the study was 33 years (range, 2, 75) and 95 (82%) were over 16 years (F:M, 69:26). In these adults, 52 (55%) were diagnosed in childhood (i.e. ≤ 16 years) and only 1 male was diagnosed in adulthood. The median body mass index (BMI) standard deviation score of children was 0.70 (−2.43, 3.15). Median BMI of adults was 28 (15, 56) and median adult and paediatric systolic BP was 120 mmHg (95, 153) and 106 mmHg (83, 130), respectively.
Conclusion
The 17OHP‐based algorithm that was used in this study represents a useful method for identifying existing cases of CAH and can allow improved understanding of routinely collected markers of clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK.
- Department of Clinical Biochemistry, Glasgow Royal Infirmary, Glasgow, UK.
- West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, UK.
- Department of Clinical Biochemistry, Royal Hospital for Children, Glasgow, UK.
ORCID-Profile: Joseph McElvaney, Syed Faisal Ahmed
Zitieren
APA
McElvaney, J., Ali, S. R., Frank, A. R., Longmuir, S., McNeilly, J., Alimussina, M., McGowan, R., & Faisal Ahmed, S. (2026). The Use of Routine Laboratory 17‐Hydroxyprogesterone for Identification of Cases of 21‐Hydroxylase Deficiency Congenital Adrenal Hyperplasia. Clinical Endocrinology. https://doi.org/10.1111/cen.70058
Vancouver
McElvaney J, Ali SR, Frank AR, Longmuir S, McNeilly J, Alimussina M, et al. The Use of Routine Laboratory 17‐Hydroxyprogesterone for Identification of Cases of 21‐Hydroxylase Deficiency Congenital Adrenal Hyperplasia. Clinical Endocrinology. 2026. doi:10.1111/cen.70058
BibTeX
@article{McElvaney2026,
author = {McElvaney, Joseph and Ali, Salma R and Frank, Amy R and Longmuir, Sophie and McNeilly, Jane and Alimussina, Malika and McGowan, Ruth and Faisal Ahmed, Syed},
title = {The Use of Routine Laboratory 17‐Hydroxyprogesterone for Identification of Cases of 21‐Hydroxylase Deficiency Congenital Adrenal Hyperplasia},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70058}
}
EUVIMED